- Industry veteran brings more than 20 years of broad operational experience in emerging-stage, private and publicly traded biotechnology companies with an established track record in global clinical development, regulatory strategy, business development, partnering, and corporate communications
- Lerodalcibep, a novel, third generation PCSK9 inhibitor in development to reduce low density lipoprotein-cholesterol and prevent and treat cardiovascular disease, has now completed Phase 3 registration-enabling studies (N=2,387); BLA submission planned for 1H’24
CINCINNATI–(BUSINESS WIRE)–LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor in development to reduce low density lipoprotein-cholesterol (LDL-C) for patients at very high and high risk of cardiovascular disease (CVD), today announced the appointment of Ingrid Choong, PhD as Chief Business Officer.
Dr. Choong brings more than 20 years of broad and diverse operational experience in emerging-stage, private and publicly traded biotechnology companies, and has an established track record spanning global clinical and regulatory development, business development and partnering, corporate communications, investor relations, and capital market financing.
LIB recently announced completion of LIBerate-CVD (n=922) and LIBerate-HR (n=922), the final two registration-enabling Phase 3 trials of Lerodalcibep. The global Phase 3 LIBerate program is a large and comprehensive registration-enabling package including four key studies (N=2,387) and a diverse population of patients with CVD, without CVD but at very high and high risk for CVD, and heterozygous and homozygous familial hypercholesterolemia (FH), dosed with Lerodalcibep once-monthly for up to 52 weeks. LIB is preparing a biologics license application (BLA) for Lerodalcibep and plans for regulatory submission in 1H’24.
“Our mission is to make Lerodalcibep available to patients around the world as expeditiously as possible,” said David Cory, Chief Executive Officer of LIB Therapeutics. “We are pleased to welcome Dr. Choong to the LIB executive team at this important stage of our evolution toward becoming a commercial-stage company. She brings a broad set of operational experience to the LIB team to support our goal of rapid global access to Lerodalcibep through multiple pathways including strategic partnerships and commercial preparation.”
“PCSK9 is a fast-growing, global market approaching $3B this year,” said Ingrid Choong, PhD, Chief Business Officer of LIB Therapeutics. “Emerging data from Phase 3 supports Lerodalcibep’s compelling clinical and patient-friendly profile as a once-monthly, single subcutaneous injection. I’m excited to join the LIB team and look forward to making this exciting new therapy available for patients and healthcare providers around the world.”
About Ingrid Choong, PhD
Prior to joining LIB Therapeutics, Dr. Choong served as Chief Business Officer at Eiger BioPharmaceuticals. As a member of the founding team at Eiger, she transitioned from the bench into executive level operational roles over the last decade including clinical and regulatory development across multiple programs and therapeutic areas, investor relations, financing, business development and corporate communications. These efforts included the US and EU approvals of Zokinvy® (lonafarnib), the first and only treatment approved to extend survival in Hutchinson-Gilford Progeria Syndrome, a rare and fatal genetic condition in children. Dr. Choong started her industry career at Sunesis Pharmaceuticals as a Principal Scientist in Lead Discovery Research.
Dr. Choong earned a BS in Chemistry from the California Institute of Technology and received a PhD in Chemistry from the University of California at Berkeley.
About Lerodalcibep
Lerodalcibep is a novel, third-generation, PCSK9 inhibitor in development to overcome the limitations of current low density lipoprotein-cholesterol (LDL-C) lowering treatments, including statins and ezetimibe, to achieve the lower LDL-C targets in recently updated national and international guidelines to treat and prevent cardiovascular disease (CVD). Lerodalcibep is being developed as a convenient, small-injection volume, once-monthly dose with long-ambient stability. Combined with sustained LDL-C reductions demonstrated in clinical trials, lerodalcibep is expected to expand treatment options for the millions of patients around the world with atherosclerotic cardiovascular disease (ASCVD), and those at very high and high risk for ASCVD, including the 30 million individuals with more severe inherited high-cholesterol called familial hypercholesterolemia (FH).
About LIB Therapeutics Inc.
LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients with cardiovascular disease and the 30 million individuals with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents.
For more information, please visit: www.libtherapeutics.com.
Contacts
Ingrid Choong, Chief Business Officer
ichoong@libtherapeutics.com